Se-Hoon Lee

Quick facts

Phase 2 pipeline

• Atezolizumab, Etoposide, Carboplatin, Tarlatamab · Oncology
  PD-L1 inhibitor
• Lazertinib group

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Se-Hoon Lee portfolio CI brief
• Se-Hoon Lee pipeline updates RSS

Related

• Sector hub: All tracked pharma companies